All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

isoprenaline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
bronchodilators, phenethylamine derivatives	1499	7683-59-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: isoprenaline isoproterenol isoproterenol hydrochloride DL-Isoproterenol isoprenalin isoprenaline sulfate DL-isoprenaline hydrochloride isoproterenol sulfate isoproterenol HCl DL-isoprenaline HCl	Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant. Molecular weight: 211.26 Formula: C11H17NO3 CLOGP: 0.15 LIPINSKI: 0 HAC: 4 HDO: 4 TPSA: 72.72 ALOGS: -1.56 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
90	mg	O
90	mg	P
0.64	mg	Inhal.aerosol
10	mg	Inhal.solution
40	mg	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.79 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	56 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.71 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.41 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	50 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
March 9, 1956	FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic epidermal necrolysis	188.91	72.69	44	337	21602	34934948

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic epidermal necrolysis	171.13	51.17	46	717	44535	79699090
Drug ineffective	95.20	51.17	79	684	1080834	78662791
Ventricular tachycardia	70.86	51.17	23	740	41912	79701713
Gallbladder rupture	52.85	51.17	9	754	973	79742652
Ventricular fibrillation	51.82	51.17	17	746	31909	79711716

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01CA02	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
ATC	R03AB02	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Non-selective beta-adrenoreceptor agonists
ATC	R03AK02	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS, INHALANTS Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC	R03CB01	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Non-selective beta-adrenoreceptor agonists
ATC	R03CB51	RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Non-selective beta-adrenoreceptor agonists
FDA MoA	N0000000245	Adrenergic beta-Agonists
FDA EPC	N0000175555	beta-Adrenergic Agonist
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D020011	Protective Agents
MeSH PA	D019141	Respiratory System Agents
MeSH PA	D013566	Sympathomimetics
CHEBI has role	CHEBI:35522	beta-adrenergic agonists
CHEBI has role	CHEBI:35523	bronchodilator
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:38147	cardiotonic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypovolemic shock	indication	39419009
Low cardiac output syndrome	indication	44088000
Common cold	indication	82272006	DOID:10459
Atrioventricular block	indication	233917008	DOID:0050820
Cardiac arrest	indication	410429000	DOID:0060319
Syncope due to Heart Block	indication
Thick Bronchial Secretions	indication
Tachyarrhythmia	contraindication	6285003
Myocardial infarction	contraindication	22298006	DOID:5844
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Diabetes mellitus	contraindication	73211009	DOID:9351
Angina pectoris	contraindication	194828000
Chronic myocardial ischemia	contraindication	413844008	DOID:3393
Disorder of coronary artery	contraindication	414024009
Digitalis Toxicity with AV Conduction Defects	contraindication
Atrioventricular Conduction Defect	contraindication
Tachycardia due to Digitalis Toxicity	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.97	acidic
pKa2	12.82	acidic
pKa3	13.92	acidic
pKa4	8.94	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	EC50	9		WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	EC50	9.80		WOMBAT-PK	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	4.92		CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.33		CHEMBL
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN	AGONIST	EC50	8.50		WOMBAT-PK
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	5.54		CHEMBL
Taste receptor type 2 member 14	GPCR	Q9NYV8	T2R14_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 46	GPCR	P59540	T2R46_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 38	GPCR	P59533	T2R38_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 39	GPCR	P59534	T2R39_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 40	GPCR	P59535	T2R40_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 41	GPCR	P59536	T2R41_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 43	GPCR	P59537	T2R43_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 31	GPCR	P59538	T2R31_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 45	GPCR	P59539	T2R45_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 30	GPCR	P59541	T2R30_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 19	GPCR	P59542	T2R19_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 20	GPCR	P59543	T2R20_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 50	GPCR	P59544	T2R50_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 60	GPCR	P59551	T2R60_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 42	GPCR	Q7RTR8	T2R42_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 16	GPCR	Q9NYV7	T2R16_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 13	GPCR	Q9NYV9	T2R13_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 10	GPCR	Q9NYW0	T2R10_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 9	GPCR	Q9NYW1	TA2R9_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 8	GPCR	Q9NYW2	TA2R8_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 7	GPCR	Q9NYW3	TA2R7_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 5	GPCR	Q9NYW4	TA2R5_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 4	GPCR	Q9NYW5	TA2R4_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 3	GPCR	Q9NYW6	TA2R3_HUMAN		EC50	8.31		CHEMBL
Taste receptor type 2 member 1	GPCR	Q9NYW7	TA2R1_HUMAN		EC50	8.31		CHEMBL
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	5.75		DRUG MATRIX
Beta-2 adrenergic receptor	GPCR		ADRB2_CAVPO		EC50	7.54		CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_BOVIN		Kd	6.48		CHEMBL
Beta-1 adrenergic receptor	GPCR		ADRB1_RAT		IC50	6.22		CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_CANFA		IC50	6		CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_MESAU		Ki	6.87		CHEMBL
Beta-3 adrenergic receptor	GPCR		ADRB3_MOUSE	AGONIST	Ki	5.30		IUPHAR
Beta-3 adrenergic receptor	GPCR		ADRB3_RAT	AGONIST	Ki	5.30		IUPHAR
Beta-1 adrenergic receptor	GPCR		ADRB1_MOUSE		Ki	6.66		CHEMBL

External reference:

ID	Source
4019793	VUID
N0000147882	NUI
D01390	KEGG_DRUG
51-30-9	SECONDARY_CAS_RN
4018235	VANDF
4018236	VANDF
4019793	VANDF
C0022245	UMLSCUI
CHEBI:64317	CHEBI
5FW	PDB_CHEM_ID
CHEMBL434	ChEMBL_ID
CHEMBL1711	ChEMBL_ID
DB01064	DRUGBANK_ID
3779	PUBCHEM_CID
536	IUPHAR_LIGAND_ID
6078-56-4	SECONDARY_CAS_RN
6054	RXNORM
2959	MMSL
4931	MMSL
4932	MMSL
71960	MMSL
d00697	MMSL
001778	NDDF
001779	NDDF
001780	NDDF
29301006	SNOMEDCT_US
372781009	SNOMEDCT_US
49602000	SNOMEDCT_US
57845006	SNOMEDCT_US
D007545	MESH_DESCRIPTOR_UI
CHEMBL3989521	ChEMBL_ID
4201	INN_ID
L628TT009W	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Isuprel	HUMAN PRESCRIPTION DRUG LABEL	1	0187-4330	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	26 sections
Isuprel	HUMAN PRESCRIPTION DRUG LABEL	1	0187-4330	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	26 sections
Isuprel	HUMAN PRESCRIPTION DRUG LABEL	1	0187-4330	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	26 sections
ISOPROTERENOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0548-9501	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	ANDA	19 sections
ISOPROTERENOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0548-9502	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	ANDA	19 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	14789-011	INJECTION, SOLUTION	0.20 mg	INTRAMUSCULAR	ANDA	27 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	14789-011	INJECTION, SOLUTION	0.20 mg	INTRAMUSCULAR	ANDA	27 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	14789-011	INJECTION, SOLUTION	0.20 mg	INTRAMUSCULAR	ANDA	27 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	14789-015	INJECTION, SOLUTION	0.20 mg	INTRAMUSCULAR	ANDA	27 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	14789-015	INJECTION, SOLUTION	0.20 mg	INTRAMUSCULAR	ANDA	27 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	14789-015	INJECTION, SOLUTION	0.20 mg	INTRAMUSCULAR	ANDA	27 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	23155-660	INJECTION, SOLUTION	0.20 mg	INTRACARDIAC	ANDA	20 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	23155-660	INJECTION, SOLUTION	0.20 mg	INTRACARDIAC	ANDA	20 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	23155-660	INJECTION, SOLUTION	0.20 mg	INTRACARDIAC	ANDA	20 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	23155-661	INJECTION, SOLUTION	0.20 mg	INTRACARDIAC	ANDA	20 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	23155-661	INJECTION, SOLUTION	0.20 mg	INTRACARDIAC	ANDA	20 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	23155-661	INJECTION, SOLUTION	0.20 mg	INTRACARDIAC	ANDA	20 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42571-294	INJECTION	0.20 mg	INTRAVENOUS	ANDA	27 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42571-294	INJECTION	0.20 mg	INTRAVENOUS	ANDA	27 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42571-330	INJECTION	0.20 mg	INTRAVENOUS	ANDA	27 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42571-330	INJECTION	0.20 mg	INTRAVENOUS	ANDA	27 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54879-039	INJECTION, SOLUTION	1 mg	INTRACARDIAC	ANDA	18 sections
Isoproterenol Hydrochloride	Human Prescription Drug Label	1	55150-316	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	ANDA	18 sections
Isoproterenol Hydrochloride	Human Prescription Drug Label	1	55150-317	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	18 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68682-433	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA authorized generic	19 sections
ISOPROTERENOL	HUMAN PRESCRIPTION DRUG LABEL	1	69097-521	INJECTION, SOLUTION	0.20 mg	INTRACARDIAC	ANDA	11 sections
ISOPROTERENOL	HUMAN PRESCRIPTION DRUG LABEL	1	69097-522	INJECTION, SOLUTION	1 mg	INTRACARDIAC	ANDA	11 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	69918-731	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	ANDA	20 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	69918-735	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	ANDA	20 sections
Isoproterenol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1604	INJECTION, SOLUTION	0.20 mg	INTRACARDIAC	ANDA	27 sections